Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
Occasionally a reader experiences a very serious medical problem and attributes it to a medication
The wellness industry has seized on this, marketing synthetic peptides as a way to 'hack' your body's natural processes
And when there are symptomsthings like fatigue, tingling hands, and feet, dizziness, and memory losstheyre often so non-specific that doctors wont always flag B12 deficiency as an obvious cause
Each is backed by years of clinical evidence, geared for chronic weight management, and available through Klinic
doi:10.1042/bj2860383